MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
Sort
Language
Type
Field
Venue
International Journal of Gynecological Cancer
Topic
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

914 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
914 works in the cohort · of 4,299,418page 10 of 19

Labels cover 3 of 914 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 914 of 914 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

afffundunlabeled
Randomized study evaluating optimal dose, efficacy, and safety of E7386 plus lenvatinib versus treatment of physician’s choice in advanced/recurrent endometrial carcinoma previously treated with platinum-based chemotherapy and immune checkpoint inhibitors
Ramez N. Eskander, Jung‐Yun Lee, Mansoor Raza Mirza, Domenica Lorusso, Helen Mackay, Isabelle Ray‐Coquard +11 more
2025· article· en· International Journal of Gynecological Cancer· Medicine
machine prediction:candidate · noneconsensus · none
1
citations
affno abstractunlabeled
462 Progression-free survival 2-progression-free survival 1 in patients with primary advanced/recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy alone in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial
Carolyn Mccourt, Graziana Ronzino, Mark S. Shahin, Rebecca Kristeleit, Lyndsay Willmott, Oleksandr Zub +14 more
2024· article· en· International Journal of Gynecological Cancer· Medicine
machine prediction:candidate · noneconsensus · none
1
citations
affno abstractunlabeled
Gallstone mimicking metastatic cervical cancer
Catherine Pouyez, Meriame Dami
2021· article· en· International Journal of Gynecological Cancer· Medicine
machine prediction:candidate · noneconsensus · none
1
citations
affno abstractunlabeled
285 Patient-reported outcomes from the phase 3, randomized, double-blind, placebo-controlled ENGOT-Cx11/GOG 3047/KEYNOTE-A18 study of pembrolizumab plus concurrent chemoradiotherapy in patients with high-risk locally advanced cervical cancer
Sandro Pignata, Vladyslav Sukhin, Nicoletta Colombo, Jacob Korach, Takashi Matsumoto, Susan Lalondrelle +14 more
2024· article· en· International Journal of Gynecological Cancer· Medicine
machine prediction:candidate · noneconsensus · none
1
citations
affno abstractunlabeled
2022-RA-660-ESGO Characterization of extended treatment benefit from three phase 1 and 3 clinical trials examining patients with folate receptor alpha-positive recurrent ovarian cancer treated with single-agent mirvetuximab soravtansine
Ana Oaknin, Domenica Lorusso, Amit M. Oza, Nicoletta Colombo, Toon Van Gorp, David M. O’Malley +11 more
2022· article· en· International Journal of Gynecological Cancer· Medicine
machine prediction:candidate · noneconsensus · none
1
citations
affno abstractunlabeled
Resisting RECIST—Uniformity Versus Clinical Validity
Michelle Wilson, Michael Friedländer, Stéphanie Lheureux, William Small, Andrés Poveda, Éric Pujade-Lauraine +5 more
2017· article· en· International Journal of Gynecological Cancer· Medicine
machine prediction:candidate · metaresearchconsensus · metaresearch
1
citations
affno abstractunlabeled
P116 ATHENA (GOG-3020/ENGOT-ov45; EudraCT 2017–004557–17; NCT03522246): a randomised, double-blind, placebo-controlled, phase 3 study of the poly(ADP-Ribose) polymerase (PARP) inhibitor rucaparib + the PD-1 inhibitor nivolumab following frontline platinum-based chemotherapy in ovarian cancer (OC)
Athina Christopoulou, Frederik Marmé, Ana Oaknin, Domenica Lorusso, Tamar Safra, Gabriel Lindahl +19 more
2019· article· en· International Journal of Gynecological Cancer· Medicine
machine prediction:candidate · noneconsensus · none
1
citations
affno abstractunlabeled
#142 An international randomized phase III trial comparing radical hysterectomy and pelvic node dissection (RH) vs simple hysterectomy and pelvic node dissection (SH) in patients with low-risk early-stage cervical cancer (LRESCC)
Marie Plante, Janice S. Kwon, Sarah E. Ferguson, Vanessa Samouëlian, Gwénaël Ferron, Amandine Maulard +14 more
2023· article· en· International Journal of Gynecological Cancer· Medicine
machine prediction:candidate · noneconsensus · none
1
citations
affno abstractunlabeled
PR049/#741  Improved risk prediction in HPV-associated endocervical adenocarcinoma through assessment of binary silva pattern-based classification: international multicenter retrospective study of the international society of gynecological pathologists
Aime Powell, Anjelica Hodgson, Paul A. Cohen, Joseph T. Rabban, Kay J. Park, W. Glenn McCluggage +2 more
2023· article· en· International Journal of Gynecological Cancer· Medicine
machine prediction:candidate · noneconsensus · none
1
citations

How this was built: Screen · Findings · About